Effects of hydromorphone-based intravenous patient-controlled analgesia with and without a low basal infusion on postoperative hypoxaemia: study protocol for a randomised controlled clinical trial. Issue 11 (16th November 2022)

• Record Type: Journal Article
• Authors: Ma, Yumei; Deng, Zhuomin; Feng, Xiangying; Luo, Jialin; Meng, Yang; Lin, Jingjing; Mu, Xiaoxiao; Yang, Xuan; Nie, Huang
• Is Part Of: BMJ open. Volume 12:Issue 11(2022)
• Publication Date: 2022-11-16
• Subjects: Pain management -- Adult anaesthesia -- Adult gastroenterology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-064581
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: When patients receive patient-controlled intravenous analgesia (PCIA), no basal infusion is always recommended, as the addition of a basal infusion increases the occurrence of postoperative opioid-induced respiratory depression. However, few studies have investigated whether low basal infusions increase the incidence of postoperative hypoxaemia relative to no basal infusion. We intend to conduct a clinical trial to test the hypothesis that PCIA with a low basal infusion does not increase the occurrence of postoperative hypoxaemia relative to PCIA with no basal infusion. Methods and analysis: This single-centre parallel randomised controlled clinical trial will be conducted with 160 patients undergoing gastrointestinal tumour surgery. The assigned nurse will set analgesic pumps (low or no basal infusion PCIA) according to block-based randomisation sequence. Other investigators and all participants will be blinded to intervention allocation. All patients will be monitored continuously with the ep pod, a wireless wearable device, recording of oxygen saturation (SpO2 ) and daily ambulation duration for 48 hours postoperatively. Three follow-up evaluations will be conducted to assess the analgesic effect (Numeric Rating Scale (NRS) pain score) and opioid-related side effects (Overall Benefit of Analgesic Score (OBAS)). The primary outcome will be the area under the curve for hypoxaemia (defined as SpO2 <95%) per hour. The secondary outcomes will be the areas under the curve for hypoxaemia defined as SpO2 <90% and <85% per hour, hydromorphone consumption, OBASs at 24 and 48 hours postoperatively, NRS scores at 4, 24 and 48 hours postoperatively, and the ambulation time per hour over 48 hours. Ethics and dissemination: The study has been approved by the Xijing Hospital Ethics Committee (KY20212163-F-1). Written informed consent will be obtained from all patients or their authorised surrogates. All data will be managed with confidentiality. Findings will be disseminated at international conferences and in peer-reviewed journals. Trial registration number: ChiCTR2100054317.